Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons

Current Opinion in HIV and AIDS

Volumn 9, Issue 1, 2014, Pages 41-47

  Ryom, Lene ^a   Mocroft, Amanda ^b   Lundgren, Jens D ^a  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

antiretroviral treatment; HIV; immune suppression; nephrotoxicity; protease inhibitors; renal impairment; tenofovir

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; ILLICIT DRUG; INTEGRASE INHIBITOR; NEVIRAPINE; NUCLEOSIDE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; DIAGNOSTIC PROCEDURE; END STAGE RENAL DISEASE; FOLLOW UP; GLOMERULUS FILTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; MITOCHONDRIAL TOXICITY; MIXED INFECTION; MODERATE RENAL IMPAIRMENT; MORTALITY; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SEVERE RENAL IMPAIRMENT; TUBULAR DYSFUNCTION; URINARY EXCRETION; VIREMIA;

ADENINE; ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSION; KIDNEY DISEASES; ORGANOPHOSPHONATES; PROTEASE INHIBITORS;

EID: 84892369108     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000023     Document Type: Review

References (50)

1. Alsauskas ZC, Medapalli RK, Ross MJ. Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients. Expert Opin Pharmacother 2011; 12: 691-704
2. Ryom L, Mocroft A, Kirk O, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: The D: A: D Study. J Infect Dis 2013; 207: 1359-1369
3. Ryom L, Kirk O, Lundgren J, et al. Advanced chronic kidney disease, endstage renal disease and renal death among HIV-positive individuals in Europe. HIV Med 2013; 14: 503-508
4. Jotwani V, Li Y, Grunfeld C, et al. Risk factors for ESRD in HIV-Infected individuals: Traditional and HIV-related factors. Am J Kidney Dis 2012; 59: 628-635
5. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24: 1667-1678
6. Kalayjian RC, Lau B, Mechekano RN, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS 2012; 26: 1907-1915
7. Harris M. Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. Expert Opin Drug Saf 2008; 7: 389-400
8. Schouten J, group oboAHs. Comorbidity and ageing with HIV. IAS, Washington DC, USA; 2012
9. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26: 867-875
10. Hamada Y, Nishijima T, Watanabe K, et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis 2012; 55: 1262-1269
11. Rockwood N, Mandalia S, Bower M, et al. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS 2011; 25: 1671-1673
12. Jose S, Hamzah L, Campbell L, et al. Reversibility of tenofovir-Associated decline in kidney function. Atlanta, Georgia, USA: CROI; 2013
13. Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results. J Acquir Immune Defic Syndr 2013; 63: 96-100
14. Campo R, Dejesus E, Bredeek UF, et al. SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis 2013; 56: 1637-1645
15. Mwafongo A, Nkanaunena K, Hosseinipour M, et al. Renal insufficiency among women treated with tenofovir/emtricitabine/lopinavir/ritonavir or tenofovir/ emtricitabine/nevirapine. Atlanta, Georgia, USA: CROI; 2013
16. Choi AI, Shlipak MG, Hunt PW, et al. HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS 2009; 23: 2143-2149
17. Arbel Y, Halkin A, Finkelstein A, et al. Impact of estimated glomerular filtration rate on vascular disease extent and adverse cardiovascular events in patients without chronic kidney disease. Can J Cardiol 2013. [Epub ahead of print
18. Ibrahim F, Hamzah L, Jones R, et al. Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients. Am J Kidney Dis 2012; 60: 539-547
19. Turin TC, Coresh J, Tonelli M, et al. One-year change in kidney function is associated with an increased mortality risk. Am J Nephrol 2012; 36: 41-49
20. http: //www.kdigo.org/clinical-practice-guidelines/pdf/CKD/KDIGO-2012- CKD-GL.pdf. KDIGO clinical practice guidelines. 2012 [Accessed 15 March 2013
21. Choi A, Scherzer R, Bacchetti P, et al. Cystatin C, albuminuria, and 5-year allcause mortality in HIV-infected persons. Am J Kidney Dis 2010; 56: 872-882
22. Achhra AC, Amin J, Law MG, et al. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS 2010; 24: 1877-1886
23. Mocroft A, Furrer HJ, Miro JM, et al. The incidence of AIDS-defining illnesses at a current CD4 count - 200 cells/ml in the post-combination antiretroviral therapy era. Clin Infect Dis 2013
24. DSMB. START Open report, 8th Review by the data and safety monitoring board. May 16 2013
25. Brennan A, Evans D, Maskew M, et al. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS 2011; 25: 1603-1609
26. European AIDS Clinical Society, EACS-Guidelines version 6 (October 2011) European AIDS Clinical Society guidelines providing clinical guidance on monitoring and treatment of HIV and various co-morbidities, including renal impairment
27. Lao CK, Gruta C, John MD, Cocohoba J. A comparison of tenofovir-Associated renal function changes in HIV-infected African Americans vs Caucasians. J Natl Med Assoc 2011; 103: 518-522
28. Zeder AJ, Hilge R, Bogner JR, Prevalence and risk factors of low grade proteinuria in HIV infected patients. 52nd Interscience Conference on Antimicrobials and Chemotherapy (ICAAC), San Francisco, USA; 2012
29. Hamada Y, Nishijima T, Watanabe K, et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis 2012; 55: 1262-1269
30. Albini L, Cesana BM, Motta D, et al. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz. J Acquir Immune Defic Syndr 2012; 59: 18-30
31. Young J, Schafer J, Fux CA, et al. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 2012; 26: 567-575
32. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-Associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-Transcriptase inhibitor-based therapy. J Infect Dis 2008; 197: 102-108
33. Tattevin P, Revest M, Chapplain JM, et al. Increased risk of renal stones in patients treated with atazanavir. Clin Infect Dis 2013; 56: 1186
34. Alexander RT, Hemmelgarn BR, Wiebe N, et al. Kidney stones and kidney function loss: A cohort study. BMJ 2012; 345: E5287
35. Ryom L, Mocroft A, Kirk O, et al. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons in D: A: D. AIDS; in press
36. Harris M, Hull M, Yip B, et al., editors. Hypophosphatemia and albuminuria are associated with older age in HIVadults receiving antiretroviral therapy (ART). 2nd international workshop on HIV and aging, Baltimore, Maryland, USA; 2011
37. Rockwood N, Nelson M, Mandalia S, et al. A comparative analysis of risk factors associated with efavirenz, darunavir/ritonavir, lopinavir/ritonavir, atazanavir/ ritonavir an renal impairment. 17th Annual Conference of the British HIV Associations, Bournemouth, United Kingdom; 2011
38. Boehringer Ingelheim Pharmaceuticals I. Highlights of prescribing information. 2012; http: //bidocs.boehringer-ingelheim.com/BIWebAccess/View Servlet.ser?docBase-renetnt&folderPath-/PrescribingInformation/PIs/ Aptivus/10003515US01.pdf [Accessed 15 March 2013
39. Highlights of prescribing information. 2012; http: //www.accessdata.fda. gov/drugsatfda-docs/label/2009/021548s021,2116s005lbl.pdf [Accessed 15 March 2013
40. Lastours DV, Silva E, Daudon M, editors. Atazanavir (ATV) and darunavir (DRV) crystalluria and high ATV and DRV concentrations in urine of asymptomatic patients receiving ATV and DRV based regimens. 52nd ICAAC interscience conference on antimicrobial agents and chemotherapy, San Francisco, USA; 2012
41. Flandre P, Pugliese P, Cuzin L, et al. Risk factors of chronic kidney disease in HIV-infected patients. CJASN 2011; 6: 1700-1707
42. Menezes AM, Torelly J Jr, Real L, et al. Prevalence and risk factors associated to chronic kidney disease in HIV-infected patients on HAART and undetectable viral load in Brazil. PLoS One 2011; 6: E26042
43. Zolopa A, Ortiz R, Sax P, et al. Comparative study of tenofovir alafenamide vs tenofovir disoproxil fumarate, each with elvitegravir, cobicistat, and emtricitabine, for HIV treatment. Atlanta, Georgia, USA: CROI; 2013
44. Kohler JJ, Hosseini SH, Green E, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest 2011; 91: 852-858
45. Stellbrink HJ, Reynes J, Lazzarin A, et al. Dolutegravir in combination therapy exhibits rapid and sustained antiviral response in ARV-naive adults: 96-week results from SPRING-1 (ING112276). Washington, USA: CROI; 2012
46. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 2012; 61: 32-40
47. Dauchy FA, Lawson-Ayayi S, de La Faille R, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int 2011; 80: 302-309
48. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47: 74-78
49. Di Mascio M, Srinivasula S, Bhattacharjee A, et al. Antiretroviral tissue kinetics: In vivo imaging using positron emission tomography. Antimicrob Agents Chemother 2009; 53: 4086-4095
50. Mugyenyi P, Walker AS, Hakim J, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): A randomised noninferiority trial. Lancet 2010; 375: 123-131